ParkinsonCanadaV1, Main, Exploration, bibRecord, 003836

COMT inhibitors in Parkinson's disease

Identifieur interne : 003836 ( Main/Exploration ); précédent : 003835; suivant : 003837

COMT inhibitors in Parkinson's disease

Auteurs : J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada]

Source :

Canadian journal of neurological sciences [ 0317-1671 ] ; 1999.

RBID : Pascal:99-0456197

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Inhibiteur enzyme, Catechol O-methyltransferase, Hépatite, Entacapone, Tolcapone, Chimiothérapie, Traitement, Toxicité, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson Agents (metabolism), Catechol O-Methyltransferase Inhibitors, Catechol O-methyltransferase, Catechols (therapeutic use), Chemotherapy, Clinical Trials as Topic, Entacapone, Enzyme Inhibitors (therapeutic use), Enzyme inhibitor, Hepatitis, Human, Humans, Levodopa (metabolism), Parkinson Disease (drug therapy), Parkinson disease, Tolcapone, Toxicity, Treatment.
MESH :
- chemical , metabolism : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Catechols, Enzyme Inhibitors.
- chemical : Catechol O-Methyltransferase Inhibitors.
- drug therapy : Parkinson Disease.
- Clinical Trials as Topic, Humans.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">COMT inhibitors in Parkinson's disease</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J." last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Universitaire de Santé de l'Estrie</s1>
<s2>Fleurimont, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre Universitaire de Santé de l'Estrie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C. L." last="Barclay">C. L. Barclay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Ottawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
<orgName type="university">Université de Calgary</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0456197</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0456197 INIST</idno>
<idno type="RBID">Pascal:99-0456197</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001176</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C70</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C70</idno>
<idno type="wicri:doubleKey">0317-1671:1999:Rivest J:comt:inhibitors:in</idno>
<idno type="wicri:Area/Main/Merge">003E23</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10451758</idno>
<idno type="wicri:Area/PubMed/Corpus">001691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001691</idno>
<idno type="wicri:Area/PubMed/Curation">001691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001691</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001691</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001691</idno>
<idno type="wicri:Area/Ncbi/Merge">000046</idno>
<idno type="wicri:Area/Ncbi/Curation">000046</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000046</idno>
<idno type="wicri:doubleKey">0317-1671:1999:Rivest J:comt:inhibitors:in</idno>
<idno type="wicri:Area/Main/Merge">003C01</idno>
<idno type="wicri:Area/Main/Curation">003836</idno>
<idno type="wicri:Area/Main/Exploration">003836</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">COMT inhibitors in Parkinson's disease</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J." last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Universitaire de Santé de l'Estrie</s1>
<s2>Fleurimont, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre Universitaire de Santé de l'Estrie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C. L." last="Barclay">C. L. Barclay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Ottawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
<orgName type="university">Université de Calgary</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (metabolism)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Catechol O-methyltransferase</term>
<term>Catechols (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Clinical Trials as Topic</term>
<term>Entacapone</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Enzyme inhibitor</term>
<term>Hepatitis</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (metabolism)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Tolcapone</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Catechols</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Hépatite</term>
<term>Entacapone</term>
<term>Tolcapone</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Alberta</li>
</region>
<settlement><li>Calgary</li>
</settlement>
<orgName><li>Université de Calgary</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J." last="Rivest">J. Rivest</name>
</noRegion>
<name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C. L." last="Barclay">C. L. Barclay</name>
<name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003836 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003836 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:99-0456197
   |texte=   COMT inhibitors in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

COMT inhibitors in Parkinson's disease

COMT inhibitors in Parkinson's disease

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.